Singapore: Takeda Pharmaceutical has partnered with Chemo-Sero-Therapeutic Research Institute for the distribution of Kaketsuken's seasonal influenza vaccine in Japan.

"We are pleased to have concluded a sales agreement on seasonal influenza vaccine with Kaketsuken. The agreement will bolster our supply of influenza vaccine and allow us to meet the demand of as many patients and medical professionals as possible," said Hitoshi Oinuma, head of Japan Vaccine Business Unit of Takeda. "This agreement reinforces Takeda's commitment to public health in Japan."

In 2014, Takeda received approval for the new drug application of Cell Culture-based Influenza vaccine for prevention of pandemic influenza, and is currently developing a cell culture-based seasonal influenza vaccine (Development code: TAK-850).